CircR2Disease is a manually curated database, which provides a comprehensive resource for circRNA deregulation in various diseases. Increasing evidences have shown that circRNAs play critical roles in transcriptional, post-transcriptional and translational regulation. Therefore, the aberrant expression of circRNAs has been associated with a group of diseases. It is significant to develop a high-quality database to deposit the deregulated circRNAs in diseases. The current version of CircR2Disease contains 725 associations between 661 circRNAs and 100 diseases by reviewing existing literatures. Each entry in the CircR2Disease contains detailed information for the circRNA–disease relationship, including circRNA name, coordinates and gene symbol, disease name, expression patterns of circRNA, experimental techniques, a brief description of the circRNA–disease relationship, year of publication and the PubMed ID. CircR2Disease provides a user-friendly interface to browse, search and download as well as to submit novel disease-related circRNAs. CircR2Disease could be very beneficial for researches to investigate the mechanism of disease-related circRNAs and explore the appropriate algorithms for predicting novel associations. Database URL: http://bioinfo.snnu.edu.cn/CircR2Disease/

Circular RNAs (circRNAs) are a large group of endogenous non-coding RNAs which are key members of gene regulatory processes. Those circRNAs in human paly significant roles in health and diseases. Owing to the characteristics of their universality, specificity and stability, circRNAs are becoming an ideal class of biomarkers for disease diagnosis, treatment and prognosis. Identification of the relationships between circRNAs and diseases can help understand the complex disease mechanism. However, traditional experiments are costly and time-consuming, and little computational models have been developed to predict novel circRNA-disease associations. In this study, a heterogeneous network was constructed by employing the circRNA expression profiles, disease phenotype similarity and Gaussian interaction profile kernel similarity. Then, we developed a computational model of KATZ measures for human circRNA-disease association prediction (KATZHCDA). The leave-one-out cross validation (LOOCV) and 5-fold cross validation were implemented to investigate the effects of these four types of similarity measures. As a result, KATZHCDA model yields the AUCs of 0.8469 and 0.7936+/-0.0065 in LOOCV and 5-fold cross validation, respectively. Furthermore, we analyze the candidate association between hsa_circ_0006054 and colorectal cancer, and results showed that hsa_circ_0006054 may function as miRNA sponge in the carcinogenesis of colorectal cancer. Overall, it is anticipated that our proposed model could become an effective resource for clinical experimental guidance.

Expressive molecular representation plays critical roles in researching drug design, while effective methods are beneficial to learning molecular representations and solving related problems in drug discovery, especially for drug-drug interactions (DDIs) prediction. Recently, a lot of work has been put forward using graph neural networks (GNNs) to forecast DDIs and learn molecular representations. However, under the current GNNs structure, the majority of approaches learn drug molecular representation from one-dimensional string or two-dimensional molecular graph structure, while the interaction information between chemical substructure remains rarely explored, and it is neglected to identify key substructures that contribute significantly to the DDIs prediction. Therefore, we proposed a dual graph neural network named DGNN-DDI to learn drug molecular features by using molecular structure and interactions. Specifically, we first designed a directed message passing neural network with substructure attention mechanism (SA-DMPNN) to adaptively extract substructures. Second, in order to improve the final features, we separated the drug-drug interactions into pairwise interactions between each drug’s unique substructures. Then, the features are adopted to predict interaction probability of a DDI tuple. We evaluated DGNN–DDI on real-world dataset. Compared to state-of-the-art methods, the model improved DDIs prediction performance. We also conducted case study on existing drugs aiming to predict drug combinations that may be effective for the novel coronavirus disease 2019 (COVID-19). Moreover, the visual interpretation results proved that the DGNN-DDI was sensitive to the structure information of drugs and able to detect the key substructures for DDIs. These advantages demonstrated that the proposed method enhanced the performance and interpretation capability of DDI prediction modeling.

CircRNAs have particular biological structure and have proven to play important roles in diseases. It is time-consuming and costly to identify circRNA-disease associations by biological experiments. Therefore, it is appealing to develop computational methods for predicting circRNA-disease associations. In this study, we propose a new computational path weighted method for predicting circRNA-disease associations. Firstly, we calculate the functional similarity scores of diseases based on disease-related gene annotations and the semantic similarity scores of circRNAs based on circRNA-related gene ontology, respectively. To address missing similarity scores of diseases and circRNAs, we calculate the Gaussian Interaction Profile (GIP) kernel similarity scores for diseases and circRNAs, respectively, based on the circRNA-disease associations downloaded from circR2Disease database (http://bioinfo.snnu.edu.cn/CircR2Disease/). Then, we integrate disease functional similarity scores and circRNA semantic similarity scores with their related GIP kernel similarity scores to construct a heterogeneous network made up of three sub-networks: disease similarity network, circRNA similarity network and circRNA-disease association network. Finally, we compute an association score for each circRNA-disease pair based on paths connecting them in the heterogeneous network to determine whether this circRNA-disease pair is associated. We adopt leave one out cross validation (LOOCV) and five-fold cross validations to evaluate the performance of our proposed method. In addition, three common diseases, Breast Cancer, Gastric Cancer and Colorectal Cancer, are used for case studies. Experimental results illustrate the reliability and usefulness of our computational method in terms of different validation measures, which indicates PWCDA can effectively predict potential circRNA-disease associations.

MicroRNAs (miRNAs) have been proved to play critical roles in diverse biological processes, including the human disease development process. Exploring the potential associations between miRNAs and diseases can help us better understand complex disease mechanisms. Given that traditional biological experiments are expensive and time-consuming, computational models can serve as efficient means to uncover potential miRNA-disease associations. This study presents a new computational model based on variational graph auto-encoder with matrix factorization (VGAMF) for miRNA-disease association prediction. More specifically, VGAMF first integrates four different types of information about miRNAs into an miRNA comprehensive similarity network and two types of information about diseases into a disease comprehensive similarity network, respectively. Then, VGAMF gets the non-linear representations of miRNAs and diseases, respectively, from those two comprehensive similarity networks with variational graph auto-encoders. Simultaneously, a non-negative matrix factorization is conducted on the miRNA-disease association matrix to get the linear representations of miRNAs and diseases. Finally, a fully connected neural network combines linear and non-linear representations of miRNAs and diseases to get the final predicted association score for all miRNA-disease pairs. In the 10-fold cross-validation experiments, VGAMF achieves an average AUC of 0.9280 on HMDD v2.0 and 0.9470 on HMDD v3.2, which outperforms other competing methods. Besides, the case studies on colon cancer and esophageal cancer further demonstrate the effectiveness of VGAMF in predicting novel miRNA-disease associations.